Cart (0) Watch list (0)
Button für mobiles Hauptmenü

Tel.: +49 6221 868023
Fax: +49 6221 8680255
info@loxo.de

IMUBIND® Plasma PAI-1 ELISA

INTENDED USE
The IMUBIND® Plasma PAI-1 ELISA is an enzyme-linked immunosorbent assay for the quantitative measurement of human Plasminogen Activator Inhibitor Type-1 (PAI-1) antigen in plasma. This assay is for in vitro diagnostic use.

EXPLANATION OF THE TEST
Plasminogen Activator Inhibitor Type-1 (PAI-1), a primary regulator of fibrinolysis, has been found in a number of different tissues, and cell types including macrophages/monocytes, hepatocytes, vascular endothelia, adipose tissue of the heart and lungs, and in platelets.1,2 The clinical interest in measuring PAI-1 in plasma is based on case studies in which levels of this serine protease inhibitor are associated with various thrombotic and fibrinolytic complications. Deficiency of PAI-1 activity is associated with bleeding disorders wherein the routine haemostatic screening tests are normal.3,4 High levels of PAI-1 activity are found in patients suffering from myocardial infarction, haemolytic uremic syndrome, and stroke.5-9 Levels of PAI-1 in the plasma of pregnant women are also correlated with gestational diabetes, reduced placental blood flow and preeclampsia.10,11,12 Patients with cirrhosis may also have elevated levels of PAI-1.13

PRINCIPLE OF THE PROCEDURE
The IMUBIND® Plasma PAI-1 ELISA uses microwells coated with a mouse monoclonal antibody directed against human PAI-1. PAI-1 standards and plasma samples are added to the wells and the antibody captures the PAI-1 antigen present during an incubation period. A peroxidase conjugated antibody against human PAI-1 is added to the well and this conjugate binds to the captured PAI-1 molecules. All unbound material is washed away and a peroxidase reactive enzyme substrate, ortho-phenylenediamine (OPD) is added to the wells. The subsequent peroxidase/substrate reaction yields a yellow colored solution. Addition of sulfuric acid stops the reaction and turns the color of the solution color orange. The absorbance of the solution is measured at 490 nm. The absorbance is directly proportional to the amount of PAI-1 present in the sample.

Category: IVD

Type: ELISA

Product Availability: Germany, Austria, Switzerland

Manufacturer: BioMedica Diagnostics Inc., Canada

For more information please contact us.


IMUBIND Plasma PAI-1 ELISA (CE, IVD)

Cat.No. 822
Article no.: 938890

Unit: 96 Tests

Code: 822

Manufacturer: BioMedica Diagnostics Inc.

Details PDF

REFERENCES

  1. Sprengers, E.D., et al. Plasminogen activator inhibitor. Blood 1987; 69: 381-87.
  2. Declerck, P.J., et al. Measurement of plasminogen activator inhibitor 1 (PAI-1) in biological fluids with a murine monoclonal antibody based enzyme-linked immunosorbent assay. Blood 1988; 71: 220-225.
  3. Schleef, R.R., et al. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. Journal of Clinical Investigation 1989; 83: 1747.
  4. Dieval, J., et al. A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1. Blood 1991; 77: 528.
  5. Hamsten, A., et al. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-8.
  6. Juhan-Vague, I., et al. On Behalf of the ECAT Study Group. Fibrinolytic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients with Angina Pectoris. Circulation 1996; 94: 2057-2063.
  7. Thögersen, A.M., et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 98: 2241-47.
  8. Bergstein, J.M., et al. Role of plasminogen activator inhibitor type-1 in the pathogenesis and outcome of the Hemolytic Uremic Syndrome. New England Journal of Medicine 1992; 327, 755-759.
  9. Margaglione, M., et al. Abnormally High Circulation Levels of Tissue Plasminogen Activator and Plasminogen Inhibitor-1 in Patients with a History of Ischemic Stroke. Arteriosclerosis and Thrombosis 1994; 14: 1741-1745.
  10. He, S., et al. Increased blood flow resistance in placental circulation and levels of plasminogen activator inhibitors type 1 and 2 in severe preeclampsia. Blood, Coagulation & Fibrinolysis 1995; 6: 703-708.
  11. Cerneca, F., et al. Coagulation and fibrinolysis changes in normal pregnancy: Increased levels of procoagulants and reduced levels of inhibitors during pregnancy include a hypercoagulable state, combined with a reactive fibrinolysis. Obstetrics & Gynecology 1997; 73: 31-36.
  12. Bellart, J., et al. Coagulation and fibrinolysis parameters in normal pregnancy and in gestational diabetes. American Journal of Perinatology 1998; 15: 479-486.
  13. Tran-Thang, C., et al. Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis. Thrombosis & Haemostasis 1989; 62: 651.
  14. EC Regulation No. 1272/2008.
  15. Collection, Transport and Processing of Blood Specimens for Plasma-Based Coagulation Assays and Molecular Hemostasis Assays; Approved Guideline – Fifth Edition. CLSI Document H21-A5, 2008; Vol. 28, No. 5.
  16. Data on file at BioMedica Diagnostics, Stamford, Connecticut, USA 06902.

Diese Webseite verwendet Cookies. Durch die Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Datenschutzerklärung X